An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-22
DOI
10.1038/s41598-019-47044-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology
- (2018) Stefanie Koristka et al. JOURNAL OF AUTOIMMUNITY
- From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
- (2018) Susann Albert et al. Oncotarget
- Biodistribution studies of ultrasmall silicon nanoparticles and carbon dots in experimental rats and tumor mice
- (2018) Nadia Licciardello et al. Nanoscale
- Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
- (2018) L. R. Loureiro et al. Blood Cancer Journal
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
- (2017) Nicola Mitwasi et al. Oncotarget
- A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
- (2017) Susann Albert et al. OncoImmunology
- Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer
- (2016) Yu Cao et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Influence of Histidine-Containing Tags on the Biodistribution of ADAPT Scaffold Proteins
- (2016) Sarah Lindbo et al. BIOCONJUGATE CHEMISTRY
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Versatile strategy for controlling the specificity and activity of engineered T cells
- (2016) Jennifer S. Y. Ma et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies
- (2016) David T. Rodgers et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
- (2016) M Cartellieri et al. Blood Cancer Journal
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- (2015) D Sommermeyer et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system
- (2014) Claudia Arndt et al. PROSTATE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Targeted Radionuclide Therapy with A 177Lu-labeled Anti-HER2 Nanobody
- (2014) Matthias D'Huyvetter et al. Theranostics
- Synthesis and radiopharmacological evaluation of 64Cu-labeled bombesin analogs featuring a bis(2-pyridylmethyl)-1,4,7-triazacyclononane chelator
- (2013) R. Bergmann et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B
- (2013) Stefanie Koristka et al. JOURNAL OF AUTOIMMUNITY
- Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system
- (2013) C Arndt et al. LEUKEMIA
- Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells
- (2013) C Arndt et al. LEUKEMIA
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses
- (2013) V. D. Fedorov et al. Science Translational Medicine
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- A Universal Strategy for Adoptive Immunotherapy of Cancer through Use of a Novel T-cell Antigen Receptor
- (2012) K. Urbanska et al. CANCER RESEARCH
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
- (2012) Kevin J. Curran et al. JOURNAL OF GENE MEDICINE
- Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells
- (2012) A. Feldmann et al. JOURNAL OF IMMUNOLOGY
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
- (2012) Christopher C Kloss et al. NATURE BIOTECHNOLOGY
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
- (2010) Marc Cartellieri et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- (2010) V Hoyos et al. LEUKEMIA
- Retargeting of T cells to prostate stem cell antigen expressing tumor cells: Comparison of different antibody formats
- (2010) Anja Feldmann et al. PROSTATE
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- Targeting of HER2-Expressing Tumors with a Site-Specifically 99mTc-Labeled Recombinant Affibody Molecule, ZHER2:2395, with C-Terminally Engineered Cysteine
- (2009) S. Ahlgren et al. JOURNAL OF NUCLEAR MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now